AveXis is a clinical-stage gene therapy company developing innovative treatments for rare and life-threatening genetic diseases.    Its initial product candidate is AVXS-101, a gene therapy product candidate that has completed Phase I clinical trial for the treatment of spinal muscular atrophy Type 1.
AveXis is a rapidly growing leader among gene therapy biotech companies and continues to establish relationships with academics, biotechnology and pharmaceutical companies, and healthcare investors.

Company Growth (employees)
Type
Public
HQ
Bannockburn, US
Founded
2010
Size (employees)
114 (est)+10%
Website
avexis.com
AveXis was founded in 2010 and is headquartered in Bannockburn, US

Key People/Management at AveXis

Jennifer Chiang

Jennifer Chiang

Business Development

AveXis Office Locations

AveXis has an office in Bannockburn
Bannockburn, US (HQ)
200 2275 Half Day Rd
Bannockburn, US (HQ)
160 2275 Half Day Rd

AveXis Financials and Metrics

AveXis Financials

AveXis's revenue was reported to be $0 in Q3, 2016
USD

Net income (Q1, 2017)

(29.7 m)

EBIT (Q1, 2017)

(30 m)

Market capitalization (16-Oct-2017)

2.9 b

Cash (31-Mar-2017)

204.5 m
AveXis's current market capitalization is $2.9 b.
USDFY, 2016

R&D expense

58.9 m

General and administrative expense

24.5 m

Operating expense total

83.4 m

EBIT

(83.4 m)
USDQ1, 2016Q2, 2016Q3, 2016Q1, 2017

R&D expense

16.1 m10.4 m14.1 m20.3 m

General and administrative expense

4.8 m5.4 m7.1 m9.6 m

Operating expense total

20.9 m15.8 m21.2 m30 m

EBIT

(20.9 m)(15.8 m)(21.2 m)(30 m)
USDFY, 2016

Cash

240.4 m

Current Assets

245.2 m

PP&E

24.2 m

Total Assets

270.6 m
USDQ1, 2016Q2, 2016Q3, 2016Q1, 2017

Cash

148.2 m131.4 m263.6 m204.5 m

Current Assets

149.7 m134.4 m267.5 m211.7 m

PP&E

5.9 m8.3 m16.8 m33.7 m

Total Assets

156 m143.1 m284.8 m247.2 m
USDFY, 2016

Net Income

(83 m)

Depreciation and Amortization

64.6 k

Accounts Payable

958 k

Cash From Operating Activities

(48 m)
USDQ1, 2016Q2, 2016Q3, 2016Q1, 2017

Net Income

(20.8 m)(15.7 m)(21.1 m)(29.7 m)

Depreciation and Amortization

11 k

Accounts Payable

580.7 k1.1 m3.7 m11.8 m

Cash From Operating Activities

(7.7 m)
Y, 2017

Financial Leverage

1.1 x
Show all financial metrics

AveXis Market Value History

Traffic Overview of AveXis

AveXis Online and Social Media Presence

AveXis Company Life and Culture

You may also be interested in